SSRI antidepressant selection and concomitant prescribing of anxiolytics and sedative-hypnotics: evidence from primary care in the United Kingdom

References

• Sussman N. Anxiolytic antidepressant augmentation. Journal of Clinical Psychiatry 1998; 59 (Suppl 5): 42–8.
   PubMed Web of Science ®Google Scholar
• Gregor KJ, Hylan TR, van Dijk PCM et al. Outpatient antidepressant utilization in a Dutch sick fund. The American Journal of Managed Care 1998; 4: 1150–60.
   PubMed Web of Science ®Google Scholar
• Bingefors K, Isacson DG. Concomitant prescribing of tranquilizers and hypnotics among patients receiving antidepressant prescriptions. Annals of Pharmacotherapy 1998; 32(5): 531–5.
   PubMed Web of Science ®Google Scholar
• Ashton H. Guidelines for the rational use of benzodiazepines: When and what to use. Drugs 1994; 48: 25–40.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Holman SL, Sayler ME et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. Journal of Clinical Psychiatry 1994; 55: 50–9.
   PubMed Web of Science ®Google Scholar
• Filteau MJ, Baruch P, Lapierre YD et al. SSRIs in anxious-agitated depression: A post-hoc analysis of 279 patients. International Clinical Psychopharmacology, 1995; 10: 51–4.
   PubMed Web of Science ®Google Scholar
• Satterlee WG, Faries D. The effects of fluoxetine on symptoms of insomnia in depressed patients. Psychopharmacology Bulletin 1995; 31: 227–37.
   PubMedGoogle Scholar
• Joffe RT, Levitt AJ, Sokolov STH. Augmentation strategies: Focus on anxiolytics. Journal of Clinical Psychiatry 1996; 57(Suppl 7)</b>: 25–31.
   Web of Science ®Google Scholar
• Dunbar GC, Cohn JB, Fabre LF et al. A comparison of paroxetine, imipramine, and placebo in depressed out-patients. British Journal of Psychiatry, 1991; 159: 394–8.
   PubMed Web of Science ®Google Scholar
• Feighner JB, Boyer WF. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. Journal of Clinical Psychiatry 1992; 53 (Suppl): 44–7.
   Google Scholar
• Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. Journal of Clinical Psychopharmacology 1993; 13 (Suppl 2): 18S-22S.
   Google Scholar
• Gagiano CA. A double-blind comparison of paroxetine and fluoxetine in patients with major depression. British Journal of Clinical Research 1993; 4: 145–52.
   Google Scholar
• Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry 1995; 56(6): 229–37.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Sayler ME. Course of psychomotor agitation during pharmacotherapy of depression: Analysis from double-blind controlled trials with fluoxetine. Depression and Anxiety 1997; 4: 294–311.
   Google Scholar
• Sheehan D, Dunbar GC, Fuell DL. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacology Bulletin 1992; 28: 138–43.
   Google Scholar
• Oswald I, Adams K. Effects of paroxetine on sleep. British Journal of Clinical Psychopharmacology 1986; 22: 97–9.
   PubMed Web of Science ®Google Scholar
• Staner L, Kerkhofs M, Detroux D, et al. Acute, sub-chronic and withdrawal sleep ECG changes during treatment with paroxetine and amitriptyline: A double-blind, randomized trial in major depression. Sleep 1995; 18: 470–7.
   PubMed Web of Science ®Google Scholar
• Saletu B, Frey R, Krupka M et al. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991; 14(5): 439–47.
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacology Bull. 1987; 23(1): 164–8.
   PubMedGoogle Scholar
• Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry 1992; 53 (Suppl 2): 21–6.
   PubMed Web of Science ®Google Scholar
• Fabre LF, Abuzzahab FS, Amin M et al. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo. Biological Psychiatry 1995; 38: 592–602.
   PubMed Web of Science ®Google Scholar
• Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clinical Therapeutics 1995; 17: 786–90.
   PubMed Web of Science ®Google Scholar
• Gregor KJ, Riley J, Downing D. Concomitant use of anxiolytics and sedative-hypnotics with selective serotonin reuptake inhibitors. Clinical Therapeutics 1996; 18(3): 521–7.
   PubMed Web of Science ®Google Scholar
• Hylan TR, Neslusan CA, Baldridge RM et al. SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. Journal of Clinical Outcomes Management 1997; 4(4): 16–22.
   Google Scholar
• Pathiyal A, Hylan TR, Jones JK et al. Prescribing of selective serotonin reuptake inhibitors, anxiolytics, and sedative-hypnotics by general practitioners in the Netherlands: A multivariate analysis. Clinical Therapeutics 1997; 19(4): 798–810.
   PubMed Web of Science ®Google Scholar
• Levin GM. Concomitant use of anxiolytic or sedative-hypnotic agents with selective serotonin reuptake inhibitors. Hospital Pharmacy 1998; 33(4): 424–6.
   Google Scholar
• Terza JV. Estimating count data models with endogenous switching: Sample selection and endogenous treatment effects. Journal of Econometrics 1998; 84: 129–54.
   Web of Science ®Google Scholar
• Ashcraft MLF, Fries, BE, Nerenz DR et al. A psychiatric patient classification system: An alternative to diagnoses-related groups. Medical Care 1989; 27(5): 543–57.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Fava M, Hoog SL et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biological Psychiatry 1998; 44: 77–87.
   PubMed Web of Science ®Google Scholar
• Zajecka J, Fawcet J, Amsterdan J et al. Safety of abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study. Journal of Clinical Psycho-pharmacology 1998; 18(3): 193–7.
   PubMed Web of Science ®Google Scholar
• Oswald I, Adam K. Effects of paroxetine on sleep. British Journal of Clinical Pharmacology 1986; 22: 97–9.
   PubMed Web of Science ®Google Scholar
• British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 1997; 34: 181–2.
   Google Scholar
• Schulberg HC, Saul M, McClelland M et al. Assessing depression in primary medical and psychiatric practices. Archives of General Psychiatry 1985; 42: 1164–70.
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Reynolds CF. Management of insomnia. New England Journal of Medicine 1997; 336: 341–6.
   PubMed Web of Science ®Google Scholar
• Hayes P, Kirkwood R. Anxiety disorders. In: DiPino JT, Talbert RL, Hayes P, Yee GC, Matzke GR, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. New York: Elsevier; 1992: 1098.
   Google Scholar